source
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.BioPharma Dive · 1mo ago↗ source
- Roche KRAS drug succeeds in head-to-head lung cancer studyThe Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.BioPharma Dive · 1mo ago↗ source
- BridgeBio gets funding for drug launch; United buys into cell therapyElsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.BioPharma Dive · 1mo ago↗ source